#2841 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENT CHARACTERISTICS ASSOCIATED WITH BETTER RESPONSE TO TOLVAPTAN TREATMENT

Abstract Background and Aims Tolvaptan treatment is indicated in patients with rapidly progressive ADPKD. The factors associated a favorable medication response are not completely analyzed. We looked into the characteristics of ADPKD who responded better to tolvaptan after three years treatment. Method Forty-one (41) patients, 18 females, 23 males, (Mayo Clinic Imaging Category, MCIC, 1C, 1D 1E, mean (SD) age 42.5 (8.6) estimated-glomerular filtration rate (e-GFR) > 25 ml/min) completed tolvaptan, were included study. Total kidney volume (TKV) was measured using Magnetic Resonance at initiation study 3 post expected e-GFR decline without calculated Mayo formula (Irazabal MV et al., JASN, 2015) compared found (e-GFR versus e-GFR). Based on same formula, End Stage Renal Disease (ESRD) prediction calculated, before (i.e. we focused difference between ESRD prior data treatment). above mentioned differences used as markers correlated series patient (age, sex, diagnosis, presence hypertension (HTN) HTN onset, affected parent, TKV, MICI, etc) univariate multivariate statistical analysis. Results median (IQR) 5.3 (-1.3, 8.7) ml/min more than had been prolonged by 1 (0, 2) (more initiation). In analysis, baseline (immediately treatment) which parent developed both positively improvement prolongation (p = 0.02, 0.047, 0.01, respectively). (β -0.9, 95%CI: -1.52 - 0.29, p 0.006), diagnosis 0.88, 0.25 1.52, 0.008) 0.57, 0.16 0.98, 0.008). addition, initial 0.001), 0.013) MCIC 1.93, 95%CI 0.46 – 3.39, greater for 1E 1C). Conclusion seems be efficient younger progressing ADPKD, well-preserved renal function, less severe family history, shorter chronicity hypertension.